In light of the well‐established role of XBP1s in oncogenic transformation, cancer progression, and the development of drug resistance in breast cancer, our study further prompted us to investigate the feasibility and therapeutic potential of targeting XBP1s in HR+/HER2− breast cancer. Here, ERBB2 is linked to breast carcinoma.